New compound class fights TB but resistance uses an efflux switch

Tuberculosis remains a major global health challenge because treating Mycobacterium tuberculosis (Mtb) requires a combination of multiple antibiotics and drug-resistant strains keep emerging. That complexity makes the search for new medicines urgent: new drugs are needed that can either replace failing agents or work alongside them to shorten treatment and overcome resistance. In work led by Jennifer Herrmann, researchers turned to a natural product-derived family of compounds called chlorotonils to see whether they could add to the anti-TB arsenal. The team tested chlorotonils against a variety of Mtb strains and found promising activity: chlorotonils showed nanomolar potency against both attenuated and virulent Mtb strains. The study sets out not only to measure how well chlorotonils kill the bacteria but also to understand how they work and how Mtb might develop resistance. That dual focus — antibacterial activity plus mechanisms of resistance — is important for judging whether a new compound could be a useful therapeutic lead or a tool for further research into how Mtb survives drug attack.

To learn how chlorotonils exert their effects and how resistance arises, the researchers combined mechanistic studies, resistance profiling, and systems biology tools. Mechanistic studies and resistance profiling in Mtb showed that chlorotonils affect both lipid and energy metabolism in the bacterium, indicating multiple stress points targeted by the compounds. The team also built a purpose-designed Mtb CRISPRi library for chemical-genomic profiling, using gene knockdown to reveal genetic factors that change sensitivity to the drug. That approach identified MmpR5/MmpL5 as a major driver of chlorotonil-resistance in Mtb. Mutations or regulatory changes affecting this system conferred resistance and also produced cross-resistance with bedaquiline. Finally, the study emphasizes the role of the MmpS5-MmpL5 efflux pump complex as a central player in how Mtb expels or tolerates these compounds. By combining targeted genetic tools and chemical testing, the research maps a direct path from compound activity to genetic mechanisms of resistance.

The findings carry two linked messages. On the positive side, chlorotonils are potent anti-Mtb compounds with activity at nanomolar concentrations against multiple strains, marking them as valuable chemical leads for drug development or as probes to study bacterial biology. On the cautionary side, the discovery that MmpR5/MmpL5 mediates resistance — and that this mechanism causes cross-resistance with bedaquiline — shows that bacteria can use existing efflux systems to blunt the impact of new drugs. That overlap matters because bedaquiline is an important drug used against resistant TB, so any new agent that shares resistance pathways could face limits in its clinical usefulness. The study highlights the importance of pairing drug discovery with deep genetic and systems-level profiling so that developers can anticipate resistance, understand efflux-mediated interactions through the MmpS5-MmpL5 pump, and design strategies to minimize cross-resistance while exploiting the potent activity of chlorotonils.